联合增强肝纤维化评分与FIB-4评分判定非酒精性脂肪性肝病患者显著纤维化
该研究纳入2001—2020年463例经肝活检的非酒精性脂肪性肝病(NAFLD)患者,计算增强肝纤维化(ELF)与FIB-4评分,以F2-F4为显著纤维化。ELF评分≥9.8且FIB-4≥1.96时阳性预测值95%,可可靠判定显著纤维化;ELF≤7.7或FIB-4≤0.30时阴性预测值95%,可排除显著纤维化。
要点
- 463例NAFLD患者中39%存在显著纤维化(F2-F4)。
- ELF评分≥9.8且FIB-4≥1.96联合阳性预测值95%,可判定显著纤维化。
- ELF≤7.7或FIB-4≤0.30联合阴性预测值95%,可排除显著纤维化。
核心结论
- ELF与FIB-4联合可为临床医生提供易获取的信息,用于对NAFLD患者进行风险分层,以决定是否转诊专科或纳入临床试验。
研究设计与样本
- 分析2001—2020年纳入的NAFLD患者临床数据与肝活检资料,计算ELF与FIB-4评分,肝活检由单一血液病理学家阅片并按NASH CRN标准评分,显著纤维化定义为F2-F4期。
主要发现
- 共纳入463例NAFLD患者:年龄48±13岁,男性31%,2型糖尿病35%,39%存在显著纤维化,平均ELF评分9.0±1.2,平均FIB-4评分1.22±1.05。
- 显著纤维化患者年龄更大、男性更常见、BMI更低但代谢综合征组分更多,ELF与FIB-4更高(p<0.0001)。
- ELF识别显著纤维化的AUC(95%CI)为0.78(0.74-0.82),FIB-4为0.79(0.75-0.83)。
- ELF评分≥9.8且FIB-4≥1.96时阳性预测值95%,可可靠判定显著纤维化(灵敏度22%,特异度>99%)。
- ELF评分≤7.7或FIB-4≤0.30时阴性预测值95%,可排除显著纤维化(灵敏度98%,特异度22%)。
关键数值与推荐
- ELF评分≥9.8且FIB-4≥1.96:阳性预测值95%,灵敏度22%,特异度>99%,用于判定显著纤维化。
- ELF评分≤7.7或FIB-4≤0.30:阴性预测值95%,灵敏度98%,特异度22%,用于排除显著纤维化。
临床怎么用
- 作者认为ELF与FIB-4联合可提供易获取的信息,用于对NAFLD患者进行风险分层,以决定是否转诊专科或纳入临床试验。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The presence of fibrosis in NAFLD is the most significant risk factor for adverse outcomes. We determined the cutoff scores of two non-invasive te sts (NITs) to rule in and rule out significant fibrosis among NAFLD patients. METHODS: Clinical data and liver biopsies were used for NAFLD patients included in this analysis (2001-2020). The enhanced liver fibrosis (ELF) and FIB-4 NITs were calculated. Liver biopsies were read by a single hematopathologist and scored by the NASH CRN criteria. Significant fibrosis was defined as stage F2-F4. RESULTS: There were 463 NAFLD patients included: 48 ± 13 years old, 31% male, 35% type 2 diabetes; 39% had significant fibrosis; mean ELF score was 9.0 ± 1.2, mean FIB-4 score was 1.22 ± 1.05. Patients with significant fibrosis were older, more commonly male, had lower BMI but more components of metabolic syndrome, higher ELF and FIB-4 (p < 0.0001). The performance of the two NITs in identifying significant fibrosis was: AUC (95% CI) = 0.78 (0.74-0.82) for ELF, 0.79 (0.75-0.83) for FIB-4. The combination of ELF score ≥9.8 and FIB-4 ≥ 1.96 returned a positive predictive value of 95% which can reliably rule in significant fibrosis (sensitivity 22%, specificity >99%), while an ELF score ≤7.7 or FIB-4 ≤ 0.30 had a negative predictive value of 95% ruling out significant fibrosis (sensitivity 98%, specificity 22%). CONCLUSIONS: The combination of ELF and FIB-4 may provide practitioners with easily obtained information to risk stratify patients with NAFLD who could be referred to specialists or for enrollment in clinical trials.
引用
- Younossi ZM, Stepanova M, Felix S, et al. The combination of the enhanced liver fibrosis and FIB-4 scores to determine significant fibrosis in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2023. PMID: 36967586. doi:10.1111/apt.17472
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。